M
Michael Baumann
Researcher at Helmholtz-Zentrum Dresden-Rossendorf
Publications - 94
Citations - 1879
Michael Baumann is an academic researcher from Helmholtz-Zentrum Dresden-Rossendorf. The author has contributed to research in topics: Cancer & Radiation therapy. The author has an hindex of 18, co-authored 90 publications receiving 1287 citations. Previous affiliations of Michael Baumann include German Cancer Research Center & Dresden University of Technology.
Papers
More filters
Journal ArticleDOI
Caring for patients with cancer in the COVID-19 era.
Joris van de Haar,L.R. Hoes,Charlotte E. Coles,Kenneth Seamon,Stefan Fröhling,Dirk Jäger,Franco Valenza,Filippo de Braud,Luigi De Petris,Luigi De Petris,Jonas Bergh,Jonas Bergh,Ingemar Ernberg,Benjamin Besse,Fabrice Barlesi,Fabrice Barlesi,Elena Garralda,Alejandro Piris-Giménez,Michael Baumann,Giovanni Apolone,Jean-Charles Soria,Josep Tabernero,Carlos Caldas,Emile E. Voest +23 more
TL;DR: How the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations ‘pandemic proof’ is reported.
Journal ArticleDOI
Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments.
TL;DR: The high heterogeneity of CSC subclones along with changes of the functional behavior of individual tumors under treatment underlines the importance of the selection of the optimal timepoint(s) of biomarker evaluation, but also provides a potential therapeutic target for combined treatment approaches with irradiation.
Journal ArticleDOI
Radiotheranostics: a roadmap for future development
Ken Herrmann,Markus Schwaiger,Jason S. Lewis,Stephen B. Solomon,Barbara J. McNeil,Michael Baumann,Sanjiv S. Gambhir,Hedvig Hricak,Ralph Weissleder +8 more
TL;DR: This Review aims to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development.
Journal ArticleDOI
Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Steffen Löck,Rosalind Perrin,Annekatrin Seidlitz,Anna Bandurska-Luque,Sebastian Zschaeck,Klaus Zöphel,Mechthild Krause,Jörg Steinbach,Jörg Kotzerke,Daniel Zips,Esther G.C. Troost,Michael Baumann +11 more
TL;DR: This study validates that residual tumour hypoxia during radiochemotherapy is a major driver of therapy resistance of HNSCC, and that hypoxic volume after the second week of treatment measured by FMISO-PET may serve as biomarker for selection of patients at high risk of loco-regional recurrence after state-of-the art radiochem therapy.
Journal ArticleDOI
Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining.
Qi Liu,Lin Ma,Trevor Jones,Luis Palomero,Miquel Angel Pujana,Haydeliz Martinez-Ruiz,Patrick K. Ha,John P. Murnane,Isabel Cuartas,Joan Seoane,Michael Baumann,Michael Baumann,Annett Linge,Mary Helen Barcellos-Hoff +13 more
TL;DR: The effect of HPV in HNSCC provides critical validation of TGFβ’s role in DNA repair proficiency and further raises the translational potential of T GFβ inhibitors in cancer therapy.